| Literature DB >> 33268939 |
Sangeeta Deka1, Deepjyoti Kalita1.
Abstract
The ongoing COVID-19 pandemic has hugely impacted the economy of many countries, and there is an acute shortage of diagnostic resources. With the exponential increase in the number of cases and necessity to screen large number of people, there is a steep increase in the demand for diagnostic kits. Pooled-sample testing is a promising strategy to screen a large population rapidly with limited resources. The aim of this work was to compile a cohesive literature review of the effectiveness and accuracy of pooled-sample testing in the detection of SARS-CoV-2 and critically analyze its limitations. Medline, Google Scholar, Embase, and preprint servers (e.g., bioRxiv) were searched for literature on pooled testing for diagnosis of COVID-19, and out of initial 60 articles/reports, nine original articles were retained. Optimal pool size (number of samples in a pool) seemed to be dependent on factors like prevalence or rate of positivity in community. In low-prevalence localities pool size of around 30 seemed to be effective as observed by some authors. All the researchers had found significant reduction in number of tests (depending on pool size, stages, and pooling design), leading to conservation of resources. Pooling can be done with extracted RNA eluate or directly with patient's sample before extraction. This leads to further reduction in consumables, time and manpower. Risk of false negativity in samples with high-threshold cycle (i.e., low-viral load) value was a concern. Some researchers suggest adding few additional cycles to lower the chances of missing positive cases with low-Ct value. Lower limit of detection (LoD) of RT-PCR kits, that is, sensitivity of kits was another factor to consider. Thus, in a country like India, given the economic benefit and scarcity of resources, pooling strategy can be very effective, especially in low-prevalence areas and in low-risk contacts. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.).Entities:
Keywords: COVID-19; RT-PCR; SARS-CoV2; group test; pooling
Year: 2020 PMID: 33268939 PMCID: PMC7684986 DOI: 10.1055/s-0040-1721159
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Newcastle-Ottawa quality assessment scale for cross-sectional studies
| Studies (First author) | Selection | Comparability | Outcome | Total score |
|---|---|---|---|---|
|
Yelin et al
| **** | ** | *** | 9* |
|
Lohse et al
| ***** | ** | ** | 9* |
|
Abdalhamid et al
| **** | ** | *** | 9* |
|
Hogan et al
| ***** | ** | ** | 9* |
|
Gupta et al
| *** | ** | ** | 7* |
|
Eberhardt et al
| **** | ** | *** | 9* |
|
Shani-Narkiss et al
| *** | * | ** | 6* |
|
Deckert et al
| **** | ** | ** | 8* |
|
Sinnott-Armstrong et al
| *** | * | ** | 6* |
Fig. 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2009 flow diagram to show the study selection process. Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7):e1000097
Studies showing dependence of optimal pool size on prevalence/positivity rates and its outcome on test efficiency. 12 15 16
| Studies |
Prevalence/positivity rate (
| Maximum pool size | Outcome |
|---|---|---|---|
|
| Prevalence | (Expressed as reduction in expected no. of tests) | |
| 1 | 11 | 80% | |
| 3 | 6 | 67% | |
| 5 | 5 | 57% | |
| 7 | 4 | 50% | |
| 10 | 4 | 41% | |
| 15 | 3 | 28% | |
|
| Prevalence | (Expressed as improvement factor) | |
| 0–3.5 | 16 (3 stages) | Improvement factor 3.8 to 16 | |
| 3.5–12 | 9 (3 stages) | Improvement factor 1.5 to 3.8 | |
| 12–30 | 3 (2 stages) | Improvement factor 1 to 1.5 | |
| 30 and above | 1 | – | |
|
|
Positivity rate (
| (Expressed as fraction of test needed) | |
| 0.04–0.2 | 4 | 0.40–0.84 | |
| 0.008–0.04 | 8 | 0.19–0.40 | |
| 0.003–0.008 | 16 | 0.11–0.18 | |
| 0.001–0.003 | 24 | 0.07–0.11 | |
| 0.0005–0.001 | 32 | 0.05–0.06 | |
| < 0.0005 | 64 | < 0.05 |
Overview of the nine studies included in the scoping review
|
Abbreviations: BAL, bronchoalveolar lavage fluid; NM, not mentioned; NPS, nasopharyngeal swab;
| ||||
|
| Study design, time horizon, target gene | Kit parameters | Pool size | Outcome and comment |
|
| 67 negative and 5 positive samples pooled to 6 different pool sizes. Target: e-gene | NM | 2,4,8, 16, 32 and 64 | 32 samples pooling can be useful with 10% false-negative result risk. |
|
| 30, 10 and individual samples sequentially. Target: e- and s-gene | NM | 30, 10 | Test capacity increased without loss of diagnostic accuracy. |
|
| Initial 5 samples pool followed by community validation (60 samples in 12 pools) | LOD: 1–3 copies/ul; | 3 to 10; experimented size 5 | Reservation of resources with 69% increase in testing capacity |
|
| Retrospective | NM | 9 and 10 | Increase testing throughput, may miss cases in low-risk setting. |
|
| Extracted RNA (240) into 35 pools (8 each) and tested in groups and individually. Gene: e and RdRp | NM | Pool of 8 samples | 8 sample pool is reliable & |
|
| Multistage group testing schemes with | NM | 3 stage with various probabilities |
With increasing
|
|
| i) Single dimension 4 pools | NM | 4 well one-dimension, 96-well (8 × 12) plate and 384-well (16 × 24) plate. |
Useful in low-prevalence countries, especially in absence of a calculated “
|
|
| Comparison of simulation of two groups | NM | Multiple pool sizes | Modeling study clearly indicating advantage of pooling approach, |
|
| Modeling study: repeated pooling in several stages and one-stage pooling | NM | Various pool sizes (mathematical consideration). | Multistage pooling is useful for big advance laboratories; one stage for other laboratories |